SCHEMBL2275173

SCHEMBL2275173

O=C(Nc1cc(OCc2ccccc2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.63
NPC1 O15118 4/20 0.63
RAB9A P51151 4/20 0.63
NR1H4 Q96RI1 3/20 0.60
CASP3 P42574 1/20 0.60
TAAR1 Q96RJ0 1/20 0.60
SENP7 Q9BQF6 1/20 0.60
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
PKM P14618 2/20 0.56
MAPT P10636 1/20 0.56
GRIK1 P39086 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
NR4A2 P43354 2/20 0.56
LTC4S Q16873 1/20 0.56
CTSV O60911 1/20 0.55
CTSL P07711 1/20 0.55
SMPD1 P17405 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC8 Q9BY41 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15233688 0.90 RAB9A (0.64) SMN1; SMN2NPC1RAB9ANR1H4CASP3
SCHEMBL2277733 0.89 KDM4E (0.64) SMN1; SMN2NPC1RAB9ANR1H4CASP3
SCHEMBL2272635 0.87 MCL1 (0.55) SMN1; SMN2NPC1RAB9ANR1H4MEN1
SCHEMBL5145407 0.87 MEN1 (0.59) SMN1; SMN2NPC1RAB9ANR1H4CASP3
SCHEMBL2290164 0.86 SMN1; SMN2 (0.76) SMN1; SMN2NPC1RAB9ANR1H4CASP3
SCHEMBL2273929 0.86 NR1H4 (0.60) SMN1; SMN2NPC1RAB9ANR1H4MEN1
SCHEMBL9724661 0.85 MAOB (0.60) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL22213598 0.81 NR1H4 (0.63) NR1H4MEN1KMT2ANR4A2CTSV
SCHEMBL2271588 0.81 SERPINE1 (0.64) NPC1RAB9ANR1H4MEN1KMT2A
SCHEMBL2935687 0.81 MEN1 (0.69) SMN1; SMN2NPC1RAB9ANR1H4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 SMN1; SMN2 3544/4885NPC1 4836/4885RAB9A 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.